ABSTRACT
The conventional experimental techniques showed that ajmaline derived from Rouwolfia serpentina Benth. biomass grown in tissue culture was effective in arresting canine ventricular arrhythmias induced by coronary occlusion, strophanthin and epinephrine, displaying antiarrhythmic effects in aconitine-induced intoxication of rats and substantially elevating the threshold of ventricular fibrillations in cats. The antiarrhythmic activity of ajmaline produced by the biotechnological technique was identical to that of ajmaline derived from the natural root of Rauwolfia serpentina Benth, which allows one to recommend that the agent in question should be clinically tested as an antiarrhythmic.
Subject(s)
Ajmaline/pharmacology , Arrhythmias, Cardiac/drug therapy , Plants, Medicinal , Rauwolfia , Ajmaline/isolation & purification , Animals , Cats , Culture Techniques , Dogs , Mice , Rats , Rats, Inbred StrainsSubject(s)
Anesthetics, Local/therapeutic use , Anti-Arrhythmia Agents/therapeutic use , Quaternary Ammonium Compounds/therapeutic use , Animals , Arrhythmias, Cardiac/drug therapy , Cardiac Complexes, Premature/drug therapy , Cats , Cell Membrane Permeability/drug effects , Dogs , Drug Evaluation , Drug Evaluation, Preclinical , Guinea Pigs , Heart/drug effects , Humans , Lidocaine/analogs & derivatives , Lidocaine/therapeutic use , Rats , Tachycardia/drug therapy , Time Factors , Trimecaine/therapeutic useABSTRACT
It has been demonstrated in experiments on cats, rabbits, white rats and mice that the quaternary derivatives of trimecaine (QDT) produce a protective and antiarrhythmic action in atrial (acetylcholine and aconitine) and ventricular (aconitine and calcium chloride) fibrillation. The relationship has been found between the characteristics of the radical at the quaternary nitrogen atom and the antiarrhythmic activity of the QDT. The effect of the QDT on the electrophysiological parameters of the myocardium not on the hemodynamics have been examined. It has been shown that the QDT might be suggested for use as new antiarrhythmic agents.